It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Whole blood transcriptional signatures distinguishing active tuberculosis patients from asymptomatic latently infected individuals exist. Consensus has not been achieved regarding the optimal reduced gene sets as diagnostic biomarkers that also achieve discrimination from other diseases. Here we show a blood transcriptional signature of active tuberculosis using RNA-Seq, confirming microarray results, that discriminates active tuberculosis from latently infected and healthy individuals, validating this signature in an independent cohort. Using an advanced modular approach, we utilise the information from the entire transcriptome, which includes overabundance of type I interferon-inducible genes and underabundance of IFNG and TBX21, to develop a signature that discriminates active tuberculosis patients from latently infected individuals or those with acute viral and bacterial infections. We suggest that methods targeting gene selection across multiple discriminant modules can improve the development of diagnostic biomarkers with improved performance. Finally, utilising the modular approach, we demonstrate dynamic heterogeneity in a longitudinal study of recent tuberculosis contacts.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Laboratory of Immunoregulation and Infection, The Francis Crick Institute, London, UK
2 Respiratory Biomedical Research Centre, Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK
3 BIOASTER Microbiology Technology Institute, Lyon, France
4 Department of Respiratory Medicine, Imperial College Healthcare NHS Trust, St Mary’s Hospital, London, UK
5 Wellcome Centre for Infectious Diseases Research, Africa, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Department of Medicine, Imperial College London, London, UK; Tuberculosis Laboratory, The Francis Crick Institute, London, UK
6 Medical Diagnostic Discovery Department, bioMérieux SA, Marcy l’Etoile, France
7 Laboratory of Immunoregulation and Infection, The Francis Crick Institute, London, UK; National Heart and Lung Institute, Imperial College London, London, UK